AneurismANEUBIONCT07233915
Genetic Profile In Patients With Ruptured and Unruptured Intracranial Aneurysms
An observational study of Aneurism, run by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta at 1 site in Italy.
Trial summary
The project will involve multiple units within our Institute (Neurosurgery, Cerebrovascular Diseases, Neurology IV), as well as additional neurosurgical centers across Italy, for the enrollment of patients with saccular intracranial aneurysms (sIA), both ruptured and unruptured. Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Aneurism
- How many people
- 252 participants
- Where
- 1 siteItaly
- Study dates
- 6 Feb 2014to Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients diagnosed with ruptured or unruptured saccular intracranial aneurysms (sIA)
Who may be able to join
- Adults aged 18 to 80 years, of both sexes
- Patients diagnosed with ruptured or unruptured saccular intracranial aneurysms (sIA)
Who cannot join
- Patients with non-saccular intracranial aneurysms
- Patients unable to provide informed consent due to language impairment or altered consciousness, in the absence of a legally appointed guardian
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site, 1 recruiting
- Recruiting
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, MI
Marco P Schiariti, MD, + 39 02.2394 ext. 2309, marco.schiariti@istituto-besta.it
About this study
Official title: Genetic Profile in Patients With Ruptured and Unruptured Intracranial Aneurysms: Observational Study Aimed at Identifying Genetic Variants Associated With the Risk of Intracranial Aneurysm Rupture
The project will involve multiple units within our Institute (Neurosurgery, Cerebrovascular Diseases, Neurology IV), as well as additional neurosurgical centers across Italy, for the enrollment of patients with saccular intracranial aneurysms (sIA), both ruptured and unruptured. Based on predefined inclusion and exclusion criteria, the recruitment target over a two-year period is 400 patients with sIA (200 ruptured, 200 unruptured) and 200 healthy controls. The study will not alter clinical practice: treatment decisions for unruptured sIA will be made independently by vascular teams according to routine standards.
For each enrolled subject, anonymized clinical data will be collected (age, sex, BMI, lifestyle habits, family history, comorbidities, aneurysmal parameters) to build an integrated database within the Biorepository. Peripheral blood samples will be obtained for genomic analyses, and when available (e.g., during clipping procedures or lumbar puncture), aneurysm wall tissue and/or cerebrospinal fluid (CSF) samples will be collected for expression studies. All materials and data (clinical/genetic) will be coded and stored at the Cryobank of the Fondazione IRCCS Istituto Neurologico Besta.
Read more
Genomic analyses: a pathway-based Genome-Wide Association Study (GWAS) is planned.
Phase I: Genotyping of 200 patients (100 with ruptured sIA, 100 with unruptured sIA) and 100 healthy controls, with combined analysis of genetic data and environmental factors related to rupture risk.
Phase II: Validation in an additional cohort of 200 patients (100 ruptured, 100 unruptured) and 100 controls to confirm the associations of identified SNPs.
Read the detailed description
This observational study aims to identify potential genetic determinants associated with the risk of rupture in saccular intracranial aneurysms (sIA). The study is conducted in collaboration with three Units of the Fondazione IRCCS Istituto Neurologico Carlo Besta in Milan (Neurosurgery Unit II, Cerebrovascular Diseases Unit, Neurology Unit IV), as well as additional neurosurgical centers across Italy, particularly for the enrollment of patients with ruptured sIA who do not present to Besta due to the absence of an Emergency Department.
As an observational study, it does not involve any modification to the routine clinical management of patients with sIA at participating centers. Specifically, the decision to propose surgical or endovascular treatment for patients with ruptured or unruptured aneurysms will be made independently of the study, based on shared criteria discussed during regular multidisciplinary vascular meetings. Furthermore, no additional follow-up is planned beyond what is routinely scheduled for patients undergoing surgical or endovascular treatment for intracranial aneurysms.
Each patient will be asked to provide informed consent through a dedicated form. Once consent is obtained, each participant will be assigned a unique alphanumeric central code, used exclusively for study purposes. Throughout the duration of the project and thereafter, only the responsible physician will be able to link the code to the patient's identity.
Patients will undergo clinical evaluation at the time of enrollment, as part of standard clinical practice. Anonymized clinical data will be recorded in a centralized database and will include: sex, age, height, weight, regular use of illicit substances, alcohol consumption, smoking habits, family history of sIA, arterial hypertension, medical history with particular attention to autoimmune diseases and recent infections, general and neurological assessment, and aneurysmal characteristics (location, maximum diameter, morphology-regular or irregular).
Each patient will also undergo peripheral venous blood sampling for genomic studies. When available (e.g., during clipping procedures or lumbar puncture performed for decompression or other clinical indications), samples of aneurysm wall tissue, subcutaneous arterial wall, and/or cerebrospinal fluid (CSF) will be collected. Biological samples, along with coded clinical and genetic data, will be stored at the Fondazione IRCCS Istituto Neurologico Carlo Besta in separate containers, housed in controlled and locked environments, to establish the first Integrated Italian Biobank for Intracranial Aneurysms.
Regarding genomic analyses, a pathway-based genome-wide association study (GWAS) will be conducted.
- Phase I: DNA extracted and genotyped from 200 patients (100 with ruptured sIA and 100 with unruptured sIA) and 100 healthy controls will be analyzed. Statistical analysis will assess the combined effect of genetic and environmental factors on rupture risk. In this phase, healthy subjects and patients with unruptured sIA will serve as control groups for patients with ruptured sIA.
- Phase II: An additional cohort of 200 patients (100 ruptured, 100 unruptured) and 100 healthy controls will be analyzed to validate the single nucleotide polymorphism (SNP) combinations identified in the preliminary phase.
Finally, the genetic and clinical data obtained from the biostatistical analysis of the entire cohort (400 patients and 200 healthy controls) will be used to develop a user-friendly computational tool aimed at estimating the individual risk of rupture in patients with sIA.
- Conditions
- Aneurism
- Keywords
- Rupture risk, Genetic factors, Observational study, Biobank, Intracranial aneurysms
- Medical subject headings
- Intracranial Aneurysm
What is being measured
The primary outcome is the main question the study is designed to answer.
Identification of genetic variants
Identification of genetic variants associated with the risk of rupture in patients with saccular intracranial aneurysms (sIA), through a pathway-based genome-wide association study (GWAS).
Measured: Within 2 years from patient enrollment and genotyping (Phase I and Phase II).
Secondary outcomes (2)
Development of a tool to estimate Rupture Risk
Development of a user-friendly computational tool to estimate individual rupture risk in patients with unruptured sIA, based on combined genetic and clinical data.
Measured: Within 3 years, following completion of biostatistical analysis.
Creation of a Biobank
Creation of an integrated biobank including biological samples (aneurysm wall, CSF, control arterial wall), genetic profiles, and anonymized clinical data from patients with ruptured and unruptured sIA.
Measured: Ongoing during the 2-year enrollment period and maintained beyond study completion.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2025
- Study start6 Feb 2014
- Primary completionDec 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (14)Papers the sponsor has linked to this study.
- Other trials for AneurismStudies of the same condition, open and under way.
- More trials run by Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 252 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07233915
- Sponsor's protocol ID
- ANEUBIO
- Acronym
- ANEUBIO
- Status last verified
- Oct 2025
- First submitted
- 14 Nov 2025
- Last updated
- 11 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Yasuno K, Bakircioglu M, Low SK, Bilguvar K, Gaal E, Ruigrok YM, Niemela M, Hata A, Bijlenga P, Kasuya H, Jaaskelainen JE, Krex D, Auburger G, Simon M, Krischek B, Ozturk AK, Mane S, Rinkel GJ, Steinmetz H, Hernesniemi J, Schaller K, Zembutsu H, Inoue I, Palotie A, Cambien F, Nakamura Y, Lifton RP, Gunel M. Common variant near the endothelin receptor type A (EDNRA) gene is associated with intracranial aneurysm risk. Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19707-12. doi: 10.1073/pnas.1117137108. Epub 2011 Nov 21.
PubMed 22106312Yasuno K, Bilguvar K, Bijlenga P, Low SK, Krischek B, Auburger G, Simon M, Krex D, Arlier Z, Nayak N, Ruigrok YM, Niemela M, Tajima A, von und zu Fraunberg M, Doczi T, Wirjatijasa F, Hata A, Blasco J, Oszvald A, Kasuya H, Zilani G, Schoch B, Singh P, Stuer C, Risselada R, Beck J, Sola T, Ricciardi F, Aromaa A, Illig T, Schreiber S, van Duijn CM, van den Berg LH, Perret C, Proust C, Roder C, Ozturk AK, Gaal E, Berg D, Geisen C, Friedrich CM, Summers P, Frangi AF, State MW, Wichmann HE, Breteler MM, Wijmenga C, Mane S, Peltonen L, Elio V, Sturkenboom MC, Lawford P, Byrne J, Macho J, Sandalcioglu EI, Meyer B, Raabe A, Steinmetz H, Rufenacht D, Jaaskelainen JE, Hernesniemi J, Rinkel GJ, Zembutsu H, Inoue I, Palotie A, Cambien F, Nakamura Y, Lifton RP, Gunel M. Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nat Genet. 2010 May;42(5):420-5. doi: 10.1038/ng.563. Epub 2010 Apr 4.
PubMed 20364137Vlak MH, Algra A, Brandenburg R, Rinkel GJ. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. Lancet Neurol. 2011 Jul;10(7):626-36. doi: 10.1016/S1474-4422(11)70109-0.
PubMed 21641282Ruigrok YM, Rinkel GJ. Genetics of intracranial aneurysms. Stroke. 2008 Mar;39(3):1049-55. doi: 10.1161/STROKEAHA.107.497305. Epub 2008 Feb 7.
PubMed 18258833Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011 Jun 15;27(12):1739-40. doi: 10.1093/bioinformatics/btr260. Epub 2011 May 5.
PubMed 21546393Kurki MI, Hakkinen SK, Frosen J, Tulamo R, von und zu Fraunberg M, Wong G, Tromp G, Niemela M, Hernesniemi J, Jaaskelainen JE, Yla-Herttuala S. Upregulated signaling pathways in ruptured human saccular intracranial aneurysm wall: an emerging regulative role of Toll-like receptor signaling and nuclear factor-kappaB, hypoxia-inducible factor-1A, and ETS transcription factors. Neurosurgery. 2011 Jun;68(6):1667-75; discussion 1675-6. doi: 10.1227/NEU.0b013e318210f001.
PubMed 21336216Juvela S. Prehemorrhage risk factors for fatal intracranial aneurysm rupture. Stroke. 2003 Aug;34(8):1852-7. doi: 10.1161/01.STR.0000080380.56799.DD. Epub 2003 Jun 26.
PubMed 12829865Juvela S. Natural history of unruptured intracranial aneurysms: risks for aneurysm formation, growth, and rupture. Acta Neurochir Suppl. 2002;82:27-30. doi: 10.1007/978-3-7091-6736-6_5.
PubMed 12378985Johnston SC, Selvin S, Gress DR. The burden, trends, and demographics of mortality from subarachnoid hemorrhage. Neurology. 1998 May;50(5):1413-8. doi: 10.1212/wnl.50.5.1413.
PubMed 9595997Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics. 2003 Feb 12;19(3):376-82. doi: 10.1093/bioinformatics/btf869.
PubMed 12584123Frosen J, Piippo A, Paetau A, Kangasniemi M, Niemela M, Hernesniemi J, Jaaskelainen J. Remodeling of saccular cerebral artery aneurysm wall is associated with rupture: histological analysis of 24 unruptured and 42 ruptured cases. Stroke. 2004 Oct;35(10):2287-93. doi: 10.1161/01.STR.0000140636.30204.da. Epub 2004 Aug 19.
PubMed 15322297de Rooij NK, Linn FH, van der Plas JA, Algra A, Rinkel GJ. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry. 2007 Dec;78(12):1365-72. doi: 10.1136/jnnp.2007.117655. Epub 2007 Apr 30.
PubMed 17470467Bilguvar K, Yasuno K, Niemela M, Ruigrok YM, von Und Zu Fraunberg M, van Duijn CM, van den Berg LH, Mane S, Mason CE, Choi M, Gaal E, Bayri Y, Kolb L, Arlier Z, Ravuri S, Ronkainen A, Tajima A, Laakso A, Hata A, Kasuya H, Koivisto T, Rinne J, Ohman J, Breteler MM, Wijmenga C, State MW, Rinkel GJ, Hernesniemi J, Jaaskelainen JE, Palotie A, Inoue I, Lifton RP, Gunel M. Susceptibility loci for intracranial aneurysm in European and Japanese populations. Nat Genet. 2008 Dec;40(12):1472-7. doi: 10.1038/ng.240. Epub 2008 Nov 9.
PubMed 18997786Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005 Jan 15;21(2):263-5. doi: 10.1093/bioinformatics/bth457. Epub 2004 Aug 5.
PubMed 15297300
Study at a glance
From the registry record, last updated by the sponsor on 11 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Genetic Profile in Patients With Ruptured and Unruptured Intracranial Aneurysms: Observational Study Aimed at Identifying Genetic Variants Associated With the Risk of Intracranial Aneurysm Rupture
- ClinicalTrials.gov ID
- NCT07233915
- Acronym / sponsor ID
- ANEUBIO / ANEUBIO
- Conditions
- Aneurism
- Keywords
- Rupture risk, Genetic factors, Observational study, Biobank, Intracranial aneurysms
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 252 participants (estimated)
- Lead sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaUniversity, hospital or other
- Study start
- 6 Feb 2014 (actual)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 18 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The project will involve multiple units within our Institute (Neurosurgery, Cerebrovascular Diseases, Neurology IV), as well as additional neurosurgical centers across Italy, for the enrollment of patients with saccular intracranial aneurysms (sIA), both ruptured and unruptured. Based on predefined inclusion and exclusion criteria, the recruitment target over a two-year period is 400 patients with sIA (200 ruptured, 200 unruptured) and 200 healthy controls. The study will not alter clinical practice: treatment decisions for unruptured sIA will be made independently by vascular teams according to routine standards.
For each enrolled subject, anonymized clinical data will be collected (age, sex, BMI, lifestyle habits, family history, comorbidities, aneurysmal parameters) to build an integrated database within the Biorepository. Peripheral blood samples will be obtained for genomic analyses, and when available (e.g., during clipping procedures or lumbar puncture), aneurysm wall tissue and/or cerebrospinal fluid (CSF) samples will be collected for expression studies. All materials and data (clinical/genetic) will be coded and stored at the Cryobank of the Fondazione IRCCS Istituto Neurologico Besta.
Genomic analyses: a pathway-based Genome-Wide Association Study (GWAS) is planned.
Phase I: Genotyping of 200 patients (100 with ruptured sIA, 100 with unruptured sIA) and 100 healthy controls, with combined analysis of genetic data and environmental factors related to rupture risk.
Phase II: Validation in an additional cohort of 200 patients (100 ruptured, 100 unruptured) and 100 controls to confirm the associations of identified SNPs.
Detailed description
This observational study aims to identify potential genetic determinants associated with the risk of rupture in saccular intracranial aneurysms (sIA). The study is conducted in collaboration with three Units of the Fondazione IRCCS Istituto Neurologico Carlo Besta in Milan (Neurosurgery Unit II, Cerebrovascular Diseases Unit, Neurology Unit IV), as well as additional neurosurgical centers across Italy, particularly for the enrollment of patients with ruptured sIA who do not present to Besta due to the absence of an Emergency Department.
As an observational study, it does not involve any modification to the routine clinical management of patients with sIA at participating centers. Specifically, the decision to propose surgical or endovascular treatment for patients with ruptured or unruptured aneurysms will be made independently of the study, based on shared criteria discussed during regular multidisciplinary vascular meetings. Furthermore, no additional follow-up is planned beyond what is routinely scheduled for patients undergoing surgical or endovascular treatment for intracranial aneurysms.
Each patient will be asked to provide informed consent through a dedicated form. Once consent is obtained, each participant will be assigned a unique alphanumeric central code, used exclusively for study purposes. Throughout the duration of the project and thereafter, only the responsible physician will be able to link the code to the patient's identity.
Patients will undergo clinical evaluation at the time of enrollment, as part of standard clinical practice. Anonymized clinical data will be recorded in a centralized database and will include: sex, age, height, weight, regular use of illicit substances, alcohol consumption, smoking habits, family history of sIA, arterial hypertension, medical history with particular attention to autoimmune diseases and recent infections, general and neurological assessment, and aneurysmal characteristics (location, maximum diameter, morphology-regular or irregular).
Each patient will also undergo peripheral venous blood sampling for genomic studies. When available (e.g., during clipping procedures or lumbar puncture performed for decompression or other clinical indications), samples of aneurysm wall tissue, subcutaneous arterial wall, and/or cerebrospinal fluid (CSF) will be collected. Biological samples, along with coded clinical and genetic data, will be stored at the Fondazione IRCCS Istituto Neurologico Carlo Besta in separate containers, housed in controlled and locked environments, to establish the first Integrated Italian Biobank for Intracranial Aneurysms.
Regarding genomic analyses, a pathway-based genome-wide association study (GWAS) will be conducted.
- Phase I: DNA extracted and genotyped from 200 patients (100 with ruptured sIA and 100 with unruptured sIA) and 100 healthy controls will be analyzed. Statistical analysis will assess the combined effect of genetic and environmental factors on rupture risk. In this phase, healthy subjects and patients with unruptured sIA will serve as control groups for patients with ruptured sIA.
- Phase II: An additional cohort of 200 patients (100 ruptured, 100 unruptured) and 100 healthy controls will be analyzed to validate the single nucleotide polymorphism (SNP) combinations identified in the preliminary phase.
Finally, the genetic and clinical data obtained from the biostatistical analysis of the entire cohort (400 patients and 200 healthy controls) will be used to develop a user-friendly computational tool aimed at estimating the individual risk of rupture in patients with sIA.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed with ruptured or unruptured saccular intracranial aneurysms (sIA)
Key inclusion criteria (2 listed)
- Adults aged 18 to 80 years, of both sexes
- Patients diagnosed with ruptured or unruptured saccular intracranial aneurysms (sIA)
Key exclusion criteria (2 listed)
- Patients with non-saccular intracranial aneurysms
- Patients unable to provide informed consent due to language impairment or altered consciousness, in the absence of a legally appointed guardian
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Identification of genetic variants
Time frame: Within 2 years from patient enrollment and genotyping (Phase I and Phase II).
Identification of genetic variants associated with the risk of rupture in patients with saccular intracranial aneurysms (sIA), through a pathway-based genome-wide association study (GWAS).
2 secondary outcomes
Development of a tool to estimate Rupture Risk
Time frame: Within 3 years, following completion of biostatistical analysis.
Creation of a Biobank
Time frame: Ongoing during the 2-year enrollment period and maintained beyond study completion.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Feb 2026.
- Background: PubMed 22106312Yasuno K, Bakircioglu M, Low SK, Bilguvar K, Gaal E, Ruigrok YM, Niemela M, Hata A, Bijlenga P, Kasuya H, Jaaskelainen JE, Krex D, Auburger G, Simon M, Krischek B, Ozturk AK, Mane S, Rinkel GJ, Steinmetz H, Hernesniemi J, Schaller K, Zembutsu H, Inoue I, Palotie A, Cambien F, Nakamura Y, Lifton RP, Gunel M. Common variant near the endothelin receptor type A (EDNRA) gene is associated with intracranial aneurysm risk. Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19707-12. doi: 10.1073/pnas.1117137108. Epub 2011 Nov 21.
- Background: PubMed 20364137Yasuno K, Bilguvar K, Bijlenga P, Low SK, Krischek B, Auburger G, Simon M, Krex D, Arlier Z, Nayak N, Ruigrok YM, Niemela M, Tajima A, von und zu Fraunberg M, Doczi T, Wirjatijasa F, Hata A, Blasco J, Oszvald A, Kasuya H, Zilani G, Schoch B, Singh P, Stuer C, Risselada R, Beck J, Sola T, Ricciardi F, Aromaa A, Illig T, Schreiber S, van Duijn CM, van den Berg LH, Perret C, Proust C, Roder C, Ozturk AK, Gaal E, Berg D, Geisen C, Friedrich CM, Summers P, Frangi AF, State MW, Wichmann HE, Breteler MM, Wijmenga C, Mane S, Peltonen L, Elio V, Sturkenboom MC, Lawford P, Byrne J, Macho J, Sandalcioglu EI, Meyer B, Raabe A, Steinmetz H, Rufenacht D, Jaaskelainen JE, Hernesniemi J, Rinkel GJ, Zembutsu H, Inoue I, Palotie A, Cambien F, Nakamura Y, Lifton RP, Gunel M. Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nat Genet. 2010 May;42(5):420-5. doi: 10.1038/ng.563. Epub 2010 Apr 4.
- Background: PubMed 21641282Vlak MH, Algra A, Brandenburg R, Rinkel GJ. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. Lancet Neurol. 2011 Jul;10(7):626-36. doi: 10.1016/S1474-4422(11)70109-0.
- Background: PubMed 18258833Ruigrok YM, Rinkel GJ. Genetics of intracranial aneurysms. Stroke. 2008 Mar;39(3):1049-55. doi: 10.1161/STROKEAHA.107.497305. Epub 2008 Feb 7.
- Background: PubMed 21546393Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011 Jun 15;27(12):1739-40. doi: 10.1093/bioinformatics/btr260. Epub 2011 May 5.
- Background: PubMed 21336216Kurki MI, Hakkinen SK, Frosen J, Tulamo R, von und zu Fraunberg M, Wong G, Tromp G, Niemela M, Hernesniemi J, Jaaskelainen JE, Yla-Herttuala S. Upregulated signaling pathways in ruptured human saccular intracranial aneurysm wall: an emerging regulative role of Toll-like receptor signaling and nuclear factor-kappaB, hypoxia-inducible factor-1A, and ETS transcription factors. Neurosurgery. 2011 Jun;68(6):1667-75; discussion 1675-6. doi: 10.1227/NEU.0b013e318210f001.
- Background: PubMed 12829865Juvela S. Prehemorrhage risk factors for fatal intracranial aneurysm rupture. Stroke. 2003 Aug;34(8):1852-7. doi: 10.1161/01.STR.0000080380.56799.DD. Epub 2003 Jun 26.
- Background: PubMed 12378985Juvela S. Natural history of unruptured intracranial aneurysms: risks for aneurysm formation, growth, and rupture. Acta Neurochir Suppl. 2002;82:27-30. doi: 10.1007/978-3-7091-6736-6_5.
- Background: PubMed 9595997Johnston SC, Selvin S, Gress DR. The burden, trends, and demographics of mortality from subarachnoid hemorrhage. Neurology. 1998 May;50(5):1413-8. doi: 10.1212/wnl.50.5.1413.
- Background: PubMed 12584123Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics. 2003 Feb 12;19(3):376-82. doi: 10.1093/bioinformatics/btf869.
- Background: PubMed 15322297Frosen J, Piippo A, Paetau A, Kangasniemi M, Niemela M, Hernesniemi J, Jaaskelainen J. Remodeling of saccular cerebral artery aneurysm wall is associated with rupture: histological analysis of 24 unruptured and 42 ruptured cases. Stroke. 2004 Oct;35(10):2287-93. doi: 10.1161/01.STR.0000140636.30204.da. Epub 2004 Aug 19.
- Background: PubMed 17470467de Rooij NK, Linn FH, van der Plas JA, Algra A, Rinkel GJ. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry. 2007 Dec;78(12):1365-72. doi: 10.1136/jnnp.2007.117655. Epub 2007 Apr 30.
- Individual participant dataSharing planned: No
Related trials for Aneurism
RecruitingObservational study
BLANDISH (Brain, Loss of Function, Aneurism, Disease, Injury, Stroke, Hemorrhage)
Intracranial Hemorrhages
Not yet recruitingObservational study
Real-World Data Collection of GORE Devices Used In the Endovascular Treatment of Aortic Aneurysms Which Incorporate Visceral Arteries.
Complex Aortic Aneurysms, Thoracoabdominal Aneurysm
Recruiting
Investigating the Tolerability and Feasibility of tVNS Following aSAH
Subarachnoid Haemorrhage From Cerebral Aneurism Rupture
Not yet recruitingObservational study
Developing Trustworthy Artificial Intelligence (AI)-Driven Tools to Predict Vascular Disease Risk and Progression: the Prospective VASCUL-AID Study
Abdominal Aorta Aneurism, Peripheral Arterial Disease
Not yet recruitingObservational study
Safety and EffecTiveness of the Silk Vista Flow DiverteR in the TrEatment of Unruptured IntracrAnial AneurysMs
Ruptured and Unruptured Intracranial Aneurysms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Aneurism, run by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marco P Schiariti, MD (+ 39 02.2394 ext. 2309, marco.schiariti@istituto-besta.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Identification of genetic variants (time frame: Within 2 years from patient enrollment and genotyping (Phase I and Phase II).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07233915, which also lists 14 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2026.